The primary objective in this study is to assess if single doses of BMS-986104 that are safe, tolerable, and result in sufficient lymphopenia (50% to 70% reduction in absolute lymphocyte count) can be achieved without bradycardia or other adverse events in healthy male subjects.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Healthy male subjects as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory evaluations will be eligible to participate in the study
• Men ages 18 to 49 years, inclusive

Exclusion Criteria:

• Any acute or chronic medical illness judged to be clinically-significant by the Investigator and/or Sponsor medical monitor
• Presence of fecal occult blood at screening
• History of prolonged occupational exposure to organic solvents or pesticides
• History of vitamin B12 deficiency and/or achlorhydria; or a vitamin B12 level at screening \